| *Disseminated on Behalf of Cardiol Therapeutics Inc.
Going Green Early, (Nasdaq: CRDL) Could Start Testing Key Technical Chart Levels Wednesday
September 3rd Greetings Readers,
Cardiol Therapeutics Inc. (Nasdaq: CRDL) steps into green pastures this morning while claiming a top spot on my radar.
And right now I'm looking at CRDL's chart. Here's what I see...
With this early green burst, CRDL has moved above both its 5-Day Simple Moving Average (SMA) and its 5-Day Exponential Moving Average (EMA).
Now, here's where things get interesting.
CRDL's 20-Day SMA and 13-Day EMA are right around $1.15.
If potential resistance breaks down early Wednesday at those levels, support could start developing and continue a recent strong vertical trend which has seen CRDL climb from a sub $.94 level back on August 8th.
Take another look at (Nasdaq: CRDL)'s chart above, read my initial report below, and consider this profile for your watchlist as key chart levels get tested this AM. -----
Progress in cardiovascular medicine is accelerating, particularly in the search for treatments for inflammatory heart disorders—conditions where few therapeutic options currently exist and patients face significant unmet needs.
Research targeting diseases such as myocarditis and pericarditis is advancing, with encouraging early findings and clinical pipelines moving closer toward meaningful solutions for individuals affected by these challenging conditions.
Driving this momentum is a life sciences company backed by seasoned leadership, united by a clear mission to tackle some of the most urgent issues in cardiac care.
As additional programs take shape, including efforts directed at heart failure, the influence of this team is gaining broader recognition across the hea.lthcare landscape—positioning their work as a notable development for anyone following innovation in heart treatment.
And with topline results recently being released and multiple analyst targets pointing to triple-digit potential upside, this under-the-radar Nasdaq profile has risen quickly to the top of my watchlist.
Consider checking out:
*Cardiol Therapeutics Inc. (Nasdaq: CRDL)*
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
And based on several potential catalysts, (Nasdaq: CRDL) takes over Wednesday's watchlist's top spot. Check them out:
#1. Advancing Therapies That Target Inflammation In The Heart!
#2. Cardiol Therapeutics Enrolling Patients In A Pivotal Phase III MAVERIC Trial.
#3. Cardiol Therapeutics Announced Phase II Topline Results For ARCHER.
#4. Multiple Analyst Targets Point To Triple-Digit Potential Upside!
#5. Near-Term Milestones Could Start Generating Serious Buzz.
But more on those in a second...
Cardiol's Immediate Focus
The company is focused on understanding how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.
Pericarditis
Pericarditis is the most common pericardial disease, responsible for about 5% of ER visits for chest pain and 5–26 hospitalizations per 100,000 people each year in the U.S.
Recurrent pericarditis develops in 15–30% of cases, impacting nearly 38,000 patients annually. Each hospitalization can cost $20k–$30k, creating a significant burden.
The only FDA-approved treatment, rilonacept, costs about $20k per month or up to $270k per year. Patients face sharp chest pain, fatigue, and repeat hospital stays, with rare but serious complications like tamponade and constrictive pericarditis. Options remain limited, underscoring the urgent need for new therapies.
Cardiol’s MAVERIC program for recurrent pericarditis has two parts. The first, a Phase II study, is already completed. The second is a pivotal Phase III trial currently enrolling patients across approximately 20 sites in the US, Canada, and Europe. This global, randomized, double-blind, placebo-controlled study is designed to determine whether CardiolRx™ can prevent disease recurrence in high-risk patients and support regulatory approval. -----
Myocarditis
Acute myocarditis is a leading cause of sudden cardiac death in people under 35 years of age.
Myocarditis is when the heart muscle gets inflamed. It can cause chest pain, trouble with how the heart works, and abnormal heart rhythms. In some cases, it can lead to severe heart failure or even sudden death, especially in people under 35.
Most often, it’s caused by a vi-rus, but it can also come from bacteria, certain medications, mRNA vaccines, or cancer treatments like chemotherapy and immune- based drugs.
CardiolRx™ was tested in the ARCHER trial, a Phase II study which took place in the US, Canada, Brazil, France, and Israel. The goal was to see if the drug is safe, well tolerated, and helps the heart recover in people with acute myocarditis. The topline results were just announced! -----
Heart Failure
Heart failure affects more than 64 million people globally and associated heal.thcare costs exceed $30Bn annually in the U.S. alone.
Heart failure is when the heart can’t pump enough blood and oxygen for the body. This can cause shortness of breath, a fast heartbeat, swelling, low energy, and trouble doing everyday activities. Many people with heart failure end up in the hospital often, and it can greatly affect quality of life.
It can be caused by heart attacks, high blood pressure, heart valve problems, heart inflammation (like myocarditis), certain cancer treatments, or inherited conditions.
CRD-38 is Cardiol’s new subcutaneously administered drug formulation targeting heart failure. They’re doing the prep work needed before starting clinical trials to see if it can become a new treatment option. -----
Product Pipeline | 
